JP7088965B2 - アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト - Google Patents
アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト Download PDFInfo
- Publication number
- JP7088965B2 JP7088965B2 JP2019568054A JP2019568054A JP7088965B2 JP 7088965 B2 JP7088965 B2 JP 7088965B2 JP 2019568054 A JP2019568054 A JP 2019568054A JP 2019568054 A JP2019568054 A JP 2019568054A JP 7088965 B2 JP7088965 B2 JP 7088965B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- substituted
- substituents selected
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517204P | 2017-06-09 | 2017-06-09 | |
| US62/517,204 | 2017-06-09 | ||
| PCT/US2018/036627 WO2018227061A1 (en) | 2017-06-09 | 2018-06-08 | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523331A JP2020523331A (ja) | 2020-08-06 |
| JP2020523331A5 JP2020523331A5 (enExample) | 2021-07-26 |
| JP7088965B2 true JP7088965B2 (ja) | 2022-06-21 |
Family
ID=62751597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568054A Active JP7088965B2 (ja) | 2017-06-09 | 2018-06-08 | アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11124494B2 (enExample) |
| EP (1) | EP3634956B1 (enExample) |
| JP (1) | JP7088965B2 (enExample) |
| KR (1) | KR102615099B1 (enExample) |
| CN (1) | CN110997653B (enExample) |
| ES (1) | ES2874352T3 (enExample) |
| WO (1) | WO2018227061A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
| EP4196471A1 (en) * | 2020-08-12 | 2023-06-21 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
| WO2024220487A1 (en) * | 2023-04-18 | 2024-10-24 | Bristol-Myers Squibb Company | Carbocyclic phenylpyrrolidinone urea fpr2 agonists |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063113A2 (en) | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57036B1 (sr) | 2013-11-28 | 2018-05-31 | Kyorin Pharmaceutical Co Ltd | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom 1 (fprl-1) |
| CN107848962B (zh) | 2015-05-27 | 2021-04-09 | 杏林制药株式会社 | 脲衍生物或其药理学上可接受的盐 |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) * | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227058A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
-
2018
- 2018-06-08 JP JP2019568054A patent/JP7088965B2/ja active Active
- 2018-06-08 EP EP18734731.5A patent/EP3634956B1/en active Active
- 2018-06-08 CN CN201880050608.1A patent/CN110997653B/zh active Active
- 2018-06-08 ES ES18734731T patent/ES2874352T3/es active Active
- 2018-06-08 US US16/619,965 patent/US11124494B2/en active Active
- 2018-06-08 KR KR1020207000305A patent/KR102615099B1/ko active Active
- 2018-06-08 WO PCT/US2018/036627 patent/WO2018227061A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063113A2 (en) | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634956B1 (en) | 2021-04-07 |
| ES2874352T3 (es) | 2021-11-04 |
| CN110997653A (zh) | 2020-04-10 |
| JP2020523331A (ja) | 2020-08-06 |
| KR102615099B1 (ko) | 2023-12-15 |
| CN110997653B (zh) | 2023-06-06 |
| US11124494B2 (en) | 2021-09-21 |
| KR20200014895A (ko) | 2020-02-11 |
| EP3634956A1 (en) | 2020-04-15 |
| US20210078971A1 (en) | 2021-03-18 |
| WO2018227061A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7088965B2 (ja) | アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト | |
| JP7094989B2 (ja) | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト | |
| JP6775560B2 (ja) | Ｊａｋ阻害剤としてのビピラゾール誘導体 | |
| JP7098663B2 (ja) | ピペリジノンホルミルペプチド２受容体アゴニスト | |
| JP2001505567A (ja) | 心臓循環系疾患の処置のための新規な置換ピラゾール誘導体 | |
| KR20100015857A (ko) | Ｓ1ｐ 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체 | |
| WO2018019222A1 (zh) | 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 | |
| TWI835476B (zh) | 哌嗪吲唑糖皮質素受體拮抗劑 | |
| JP2006525309A (ja) | ピロロ（１，２−ｂ）ピリダジン化合物、ならびにＣＲＦ−１受容体拮抗薬としてのその使用 | |
| WO2024220487A1 (en) | Carbocyclic phenylpyrrolidinone urea fpr2 agonists | |
| KR20250172673A (ko) | 카르보시클릭 페닐피롤리디논 우레아 fpr2 효능제 | |
| CN120936594A (zh) | 吡咯烷酮脲fpr2激动剂 | |
| WO2024220482A1 (en) | Pyrrolidinone urea fpr2 agonists | |
| JP7034284B2 (ja) | ムスカリン性ｍ１受容体ポジティブアロステリックモジュレーターとしての置換アザ環 | |
| KR20250175328A (ko) | 피롤리디논 우레아 fpr2 효능제 | |
| WO2023030215A1 (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
| JP2024509142A (ja) | Ｈｃｎ２調節剤として有用なピリミジン又はピリジン誘導体 | |
| KR20250172674A (ko) | 피롤리디논 우레아 fpr2 효능제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210607 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210607 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220428 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220531 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220609 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7088965 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |